News

SWOG researchers have found that starting pembrolizumab before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma.

Ramucirumab plus pembrolizumab combination reduced risk of death by 31 percent compared to standard of care in patients with advanced non-small cell lung cancer that had progressed on prior immunotherapy.

S0931 found everolimus after surgery tended to increase recurrence-free survival time in patients with high-risk kidney cancer, although results narrowly missed reaching statistical significance

Affordable Care Act’s expansion of Medicaid in 2014 was followed by a significant rise in proportion of enrollees in group’s cancer trials insured by Medicaid.

A high rate of response to neoadjuvant PD-1 blockade in patients with desmoplastic melanoma suggests such therapy could reduce the extent of surgery needed on the face and neck.

SWOG researchers have used methylation patterns in cell-free DNA from blood samples to predict which patients with muscle-invasive bladder cancer are likely to benefit from neoadjuvant chemo and which patients can safely skip it.

Adding standing physician orders to electronic record systems did not improve adherence to guidelines for prophylactic prescribing of colony-stimulating factors for febrile neutropenia for patients on high-risk or low-risk chemotherapy.

Reversing resistance to PD-1 inhibitors with combination immunotherapy in patients with advanced melanoma